ArticleWorld journal of urology2026
Analysis of functional urological surgery trends 2013-2024 in England using the HES database.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review recent trends in common functional urology surgery in England, using the Hospital Episode Statistics (HES) database. PATIENTS AND
methodsData between 2013 and 2024 were obtained from the HES database, a publicly available dataset recording details about procedures in NHS England. We recorded the procedures for treatment of female stress urinary incontinence (SUI), urgency urinary incontinence (UUI), post-prostatectomy incontinence (PPI), vesicovaginal fistula (VVF) and benign prostatic enlargement (BPE) surgery.
resultsEarly in the study period, the most common procedures for SUI were insertion of transobturator and tension-free vaginal tape (8319 procedures/year). We observe an almost complete halt in tape insertion and an increase in removal from 2019 (8 procedures/year), due to concerns about complications and the 'mesh pause' in the UK. Injection of bulking agents became the mainstream treatment from 2019 (2490 procedures/year). For refractory UUI, intravesical Botulinum toxin A (BTX) remains the preferred treatment modality (9842 procedures/year). No significant increases in neuromodulation were observed (762/year), and numbers remain low for ileocystoplasty (100/year). Transurethral Resection of the Prostate (TURP) remains the commonest operation for BPE with 15,579 cases in 2023-2024. Laser resection modalities (Holmium laser Enucleation, or HoLEP, and Photoselective Vaporization of the Prostate, or PVP) saw increases with 5098 cases in 2023-2024. VVF repair numbers remain low, averaging 83 per year. There was a reduction in overall surgical numbers during the COVID-19 pandemic, with a partial recovery from 2022 onwards.
conclusionDue to concerns around tape-related complications, bulking agents are now the mainstream treatment of SUI in women, and BTX in UUI. Whilst the use of laser is becoming increasingly popular, TURP remains the commonest procedure performed for BPE. There has only been a partial recovery in surgical numbers following the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.